Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

被引：0
|
作者：
Albiges, L. [1 ]
Rini, B. I. [2 ]
Haanen, J. B. A. G. [3 ]
Motzer, R. J. [4 ]
Kollmannsberger, C. K. [5 ]
Negrier, S. [6 ]
Nole, F. [7 ]
Bedke, J. [8 ]
Bilen, M. A. [9 ]
Nathan, P. [10 ,11 ]
Tomita, Y. [12 ]
Huang, B. [13 ]
Ching, K. A. [14 ]
Chudnovsky, A. [15 ]
Robbins, P. B. [16 ]
di Pietro, A. [17 ]
Thomaidou, D. [18 ]
Choueiri, T. K. [19 ,20 ]
机构：
[1] Inst Gustave Roussy, Med Oncol, Villejuif, France
[2] Cleveland Clin, Oncol, Cleveland, OH 44106 USA
[3] Netherlands Canc Inst, Med Oncol, Amsterdam, Netherlands
[4] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[5] British Columbia Canc Agcy, Dept Med Oncol, Vancouver Ctr, Vancouver, BC, Canada
[6] Univ Lyon, Ctr Leon Berard, Med Oncol, Lyon, France
[7] Ist Europeo Oncol, Med Oncol Div Urogenital & Head & Neck Tumours, Milan, Italy
[8] Univ Tubingen, Urol, Tubingen, Germany
[9] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA
[10] Mt Vernon Canc Ctr, Canc Serv, London, England
[11] East North Herts NHS Trust, London, England
[12] Niigata Univ, Dept Urol, Dept Mol Oncol, Grad Sch Med, Niigata, Japan
[13] Pfizer Inc, Biostat, Groton, CT 06340 USA
[14] Pfizer Inc, Biostat, San Diego, CA USA
[15] Pfizer Inc, Immunooncol, Cambridge, MA USA
[16] Pfizer Inc, Translat Oncol, San Diego, CA USA
[17] Pfizer Inc, Clin Dev, Milan, Italy
[18] Pfizer Hellas, Med Affairs, Athens, Greece
[19] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Dept Genitourinary Oncol, Boston, MA 02115 USA
[20] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
908PD
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
    Lu, Peiyao
    Liang, Weiting
    Li, Jiahao
    Hong, Yanming
    Chen, Zhuojia
    Liu, Tao
    Dong, Pei
    Huang, Hongbing
    Zhang, Tiantian
    Jiang, Jie
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [32] First-line nivolumab plus cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
    Porta, C. G.
    Burotto, M.
    Suarez Rodriguez, C.
    Bourlon, M. T.
    Hsieh, J.
    Shah, A. Y.
    Hamzaj, A.
    Bedke, J.
    Pook, D.
    Kessler, R.
    Tomita, Y.
    Drakaki, A.
    Zhang, J.
    Simsek, B.
    Schwab, G.
    Escudier, B.
    Motzer, R. J.
    Choueiri, T. K.
    Apolo, A. B.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S688 - S689
  • [33] Association of C-reactive protein (CRP) with efficacy of avelumab plus axitinib (A plus Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.
    Tomita, Yoshihiko
    Larkin, James
    Venugopal, Balaji
    Haanen, John B. A. G.
    Kanayama, Hiro-Omi
    Eto, Masatoshi
    Grimm, Marc-Oliver
    Fujii, Yosuke
    Umeyama, Yoshiko
    Mariani, Mariangela
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Nivolumab plus ipilimumab (N plus I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
    Albiges, L.
    Tannir, N.
    Burotto, M.
    McDermott, D. F.
    Plimack, E. R.
    Barthelemy, P.
    Porta, C. G.
    Powles, T. B.
    Donskov, F.
    George, S.
    Kollmannsberger, C.
    Gurney, H.
    Grimm, M-O.
    Tomita, Y.
    Castellano Gauna, D.
    Rini, B. I.
    Choueiri, T. K.
    Saggi, S. S.
    McHenry, M. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S559 - S560
  • [35] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Tannir, Nizar M.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael Anthony
    McDermott, David F.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Bracarda, Sergio
    Tykodi, Scott S.
    Powles, Thomas
    Rini, Brian I.
    Tomita, Yoshihiko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [36] Real-world effectiveness and safety of first-line (1L) avelumab plus axitinib in patients with advanced renal cell carcinoma (aRCC): Primary analysis of the AVION study.
    Merseburger, Axel Stuart
    Baklanova, Olga
    Garlonta, Victor T.
    Androulakis, Nikolaos E. M.
    Christopoulou, Athina
    Timotheadou, Eleni
    Demey, Wim
    Janssen, Jan
    Ivanyi, Philipp
    Brouwers, Barbara Anna Henk
    Wynendaele, Wim
    Wang, Lusha
    Kostkova, Lenka
    Hoffman, Jason
    Manzel, Arndt
    Koumarianou, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [37] Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Choueiri, Toni K.
    McDermott, David F.
    Powles, Thomas
    Yao, Jin
    Ammar, Ron
    Papillon-Cavanagh, Simon
    Saggi, Shruti S.
    McHenry, Brent M.
    Ross-Macdonald, Petra
    Wind-Rotolo, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
    Yan, X. Q.
    Yey, M. J.
    Zou, Q.
    Chen, P.
    He, Z. S.
    Wu, B.
    He, D. L.
    He, C. H.
    Xue, X. Y.
    Ji, Z. G.
    Chen, H.
    Zhang, S.
    Liu, Y. P.
    Zhang, X. D.
    Fu, C.
    Xu, D. F.
    Qiu, M. X.
    Lv, J. J.
    Huang, J.
    Ren, X. B.
    Cheng, Y.
    Qin, W. J.
    Zhang, X.
    Zhou, F. J.
    Ma, L. L.
    Guo, J. M.
    Ding, D. G.
    Wei, S. Z.
    He, Y.
    Guo, H. Q.
    Shi, B. K.
    Liu, L.
    Liu, F.
    Hu, Z. Q.
    Jin, X. M.
    Yang, L.
    Zhu, S. X.
    Liu, J. H.
    Huang, Y. H.
    Xu, T.
    Liu, B.
    Sun, T.
    Wang, Z. J.
    Jiang, H. W.
    Yu, D. X.
    Zhou, A. P.
    Jiang, J.
    Luan, G. D.
    Jin, C. L.
    Xu, J.
    ANNALS OF ONCOLOGY, 2024, 35 (02) : 190 - 199
  • [39] Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
    McDermott, D. F.
    Rini, B. I.
    Motzer, R. J.
    Tannir, N. M.
    Escudier, B.
    Kollmannsberger, C. K.
    Hammers, H. J.
    Porta, C.
    George, S.
    Donskov, F.
    Gurney, H. P.
    Grimm, M-O.
    Harrison, M.
    Hutson, T. E.
    Doan, J.
    Yang, S.
    Rao, S.
    Mekan, S.
    Ambavane, A.
    Powles, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 309 - 309
  • [40] Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Bourlon, M. T.
    Zurawski, B.
    Oyervides Juarez, V. M.
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Barrios, C. H.
    Richardet, M.
    Pook, D.
    Tomita, Y.
    Escudier, B.
    Zhang, J.
    Simsek, B.
    Apolo, A. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1159 - S1159
12345